Metabolic Endotoxemia is a condition that is driven by gut dysbiosis and bacterial endotoxins, known as lipopolysaccharides. The systemic increase in LPS contributes to low-grade chronic inflammation, a key characteristic of chronic disease development and progression. Key strategies to address the dysfunctions in the microbiota, the mucosal immune response and barrier structures to restore resilience in the gut microbiome will be explored in this briefing.

Sponsored by FNCE® Expo Briefing Sponsor: Microbiome Labs